-
1.发明授权公开(公告)号：US08273534B2
公开(公告)日：2012-09-25
申请号：US12465503
申请日：2009-05-13
申请人： Joffre B. Baker , Drew Watson , Tara Maddala , Steven Shak , David J. Mauro , Shirin K. Ford
发明人： Joffre B. Baker , Drew Watson , Tara Maddala , Steven Shak , David J. Mauro , Shirin K. Ford
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/158
摘要： The present invention provides methods and compositions to facilitate determining whether an EGFR-expressing cancer in an individual is an EGFR inhibitor-responsive cancer, as well as methods for determining the likelihood that a patient having an EGFR-expressing cancer will exhibit a beneficial response to an EGFR inhibitor therapy. The methods generally involve determining a normalized expression level of a gene product that correlates with EGFR inhibitor responsiveness.
摘要翻译： 本发明提供了有助于确定个体中EGFR表达的EGFR是否是EGFR抑制剂反应性癌症的方法和组合物，以及用于确定具有EGFR表达癌症的患者的可能性将表现出对 EGFR抑制剂治疗。 所述方法通常涉及确定与EGFR抑制剂反应性相关的基因产物的归一化表达水平。
-
2.发明授权Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators 有权用于确定对表皮生长因子受体调节剂敏感性的生物标志物和方法公开(公告)号：US08129114B2
公开(公告)日：2012-03-06
申请号：US11990713
申请日：2006-08-24
申请人： Shirin K. Ford , Edwin A. Clark , Xin Huang
发明人： Shirin K. Ford , Edwin A. Clark , Xin Huang
IPC分类号： C12Q1/68 , G01N33/574 , A61K39/395
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/136 , G01N33/57419 , G01N2333/485 , G01N2333/70596 , G01N2333/71 , G01N2800/52
摘要： EGFR biomarkers useful in a method for predicting the likelihood that a mammal that will respond therapeutically to a method of treating cancer comprising administering an EGFR modulator, wherein the method comprises (a) measuring in the mammal the level of at least one biomarker selected from epiregulin and amphiregulin, (b) exposing a biological sample from the mammal to the EGFR modulator, and (c) following the exposing of step (b), measuring in the biological sample the level of the at least one biomarker, wherein an increase in the level of the at least one biomarker measured in step (c) compared to the level of the at least one biomarker measured in step (a) indicates an increased likelihood that the mammal will respond therapeutically to the method of treating cancer.
摘要翻译： EGFR生物标志物可用于预测将对治疗癌症治疗的治疗反应的哺乳动物的可能性的方法，其包括施用EGFR调节剂，其中所述方法包括（a）在哺乳动物中测量至少一种选自上皮蛋白的生物标志物 （b）将生物样品从哺乳动物暴露于EGFR调节剂，和（c）在暴露步骤（b）之后，在生物样品中测量至少一种生物标志物的水平，其中增加 与步骤（a）中测量的至少一种生物标志物的水平相比，在步骤（c）中测量的至少一种生物标志物的水平表明哺乳动物对治疗癌症的方法治疗反应的可能性增加。
-
3.发明申请公开(公告)号：US20120270228A1
公开(公告)日：2012-10-25
申请号：US13542323
申请日：2012-07-05
申请人： Joffre B. Baker , Drew Watson , Tara Maddala , Steven Shak , David J. Mauro , Shirin K. Ford
发明人： Joffre B. Baker , Drew Watson , Tara Maddala , Steven Shak , David J. Mauro , Shirin K. Ford
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/158
摘要： The present invention provides methods and compositions to facilitate determining whether an EGFR-expressing cancer in an individual is an EGFR inhibitor-responsive cancer, as well as methods for determining the likelihood that a patient having an EGFR-expressing cancer will exhibit a beneficial response to an EGFR inhibitor therapy. The methods generally involve determining a normalized expression level of a gene product that correlates with EGFR inhibitor responsiveness.
摘要翻译： 本发明提供了有助于确定个体中EGFR表达的EGFR是否是EGFR抑制剂反应性癌症的方法和组合物，以及用于确定具有EGFR表达癌症的患者的可能性将表现出对 EGFR抑制剂治疗。 所述方法通常涉及确定与EGFR抑制剂反应性相关的基因产物的归一化表达水平。
-
4.发明申请BIOMARKERS AND METHODS FOR DETERMINING SENSITIVITY TO EPIDERMAL GROWTH FACTOR RECEPTOR MODULATORS 审中-公开生物标记物和测定敏感性的方法，用于生物生长因子受体调节剂公开(公告)号：US20120195889A1
公开(公告)日：2012-08-02
申请号：US13372824
申请日：2012-02-14
申请人： Shirin K. Ford , Edwin A. Clark , Xin Huang
发明人： Shirin K. Ford , Edwin A. Clark , Xin Huang
IPC分类号： A61K39/395 , C12Q1/68 , A61P35/00 , C40B30/04
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/136 , G01N33/57419 , G01N2333/485 , G01N2333/70596 , G01N2333/71 , G01N2800/52
摘要： EGFR biomarkers useful in a method for predicting the likelihood that a mammal that will respond therapeutically to a method of treating cancer comprising administering an EGFR modulator, wherein the method comprises (a) measuring in the mammal the level of at least one biomarker selected from epiregulin and amphiregulin, (b) exposing a biological sample from the mammal to the EGFR modulator, and (c) following the exposing of step (b), measuring in the biological sample the level of the at least one biomarker, wherein an increase in the level of the at least one biomarker measured in step (c) compared to the level of the at least one biomarker measured in step (a) indicates an increased likelihood that the mammal will respond therapeutically to the method of treating cancer.
摘要翻译： EGFR生物标志物可用于预测将对治疗癌症治疗的治疗反应的哺乳动物的可能性的方法，其包括施用EGFR调节剂，其中所述方法包括（a）在哺乳动物中测量至少一种选自上皮蛋白的生物标志物 （b）将生物样品从哺乳动物暴露于EGFR调节剂，和（c）在暴露步骤（b）之后，在生物样品中测量至少一种生物标志物的水平，其中增加 与步骤（a）中测量的至少一种生物标志物的水平相比，在步骤（c）中测量的至少一种生物标志物的水平表明哺乳动物对治疗癌症的方法治疗反应的可能性增加。
-
5.发明申请Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators 审中-公开用于确定对表皮生长因子受体调节剂敏感性的生物标志物和方法公开(公告)号：US20100190150A1
公开(公告)日：2010-07-29
申请号：US10585261
申请日：2005-01-07
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , G01N33/574 , G01N33/74 , G01N2500/00 , G01N2800/52
摘要： EGFR biomarkers useful in a method for identifying a mammal that will respond therapeutically to a method of treating cancer comprising administering an EGFR modulator, wherein the method comprises (a) exposing the mammal to the EGFR modulator and (b) measuring in the mammal the level of the at least one biomarker, wherein a difference in the level of the at least one biomarker measured in (b) compared to the level of the biomarker in a mammal that has not been exposed to the EGFR modulator indicates that the mammal will respond therapeutically to the method of treating cancer.
摘要翻译： EGFR生物标志物可用于鉴定将对治疗癌症治疗的治疗反应的哺乳动物的方法，其包括施用EGFR调节剂，其中所述方法包括（a）将哺乳动物暴露于EGFR调节剂和（b）在哺乳动物中测量水平 的至少一种生物标志物，其中在（b）中测量的至少一种生物标志物水平的差异与尚未暴露于EGFR调节剂的哺乳动物中的生物标志物的水平相比表明哺乳动物将在治疗 涉及治疗癌症的方法。
-
6.发明申请公开(公告)号：US20090298701A1
公开(公告)日：2009-12-03
申请号：US12465503
申请日：2009-05-13
申请人： Joffre B. Baker , Drew Watson , Tara Maddala , Steven Shak , David J. Mauro , Shirin K. Ford
发明人： Joffre B. Baker , Drew Watson , Tara Maddala , Steven Shak , David J. Mauro , Shirin K. Ford
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/158
摘要： The present invention provides methods and compositions to facilitate determining whether an EGFR-expressing cancer in an individual is an EGFR inhibitor-responsive cancer, as well as methods for determining the likelihood that a patient having an EGFR-expressing cancer will exhibit a beneficial response to an EGFR inhibitor therapy. The methods generally involve determining a normalized expression level of a gene product that correlates with EGFR inhibitor responsiveness.
摘要翻译： 本发明提供了有助于确定个体中EGFR表达的EGFR是否是EGFR抑制剂反应性癌症的方法和组合物，以及用于确定具有EGFR表达癌症的患者的可能性将表现出对 EGFR抑制剂治疗。 所述方法通常涉及确定与EGFR抑制剂反应性相关的基因产物的归一化表达水平。
-
7.发明申请Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators 有权用于确定对表皮生长因子受体调节剂敏感性的生物标志物和方法公开(公告)号：US20100221754A1
公开(公告)日：2010-09-02
申请号：US11990713
申请日：2006-08-24
申请人： Shirin K. Ford , Edwin A. Clark , Xin Huang
发明人： Shirin K. Ford , Edwin A. Clark , Xin Huang
IPC分类号： G01N33/574
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/136 , G01N33/57419 , G01N2333/485 , G01N2333/70596 , G01N2333/71 , G01N2800/52
摘要： EGFR biomarkers useful in a method for predicting the likelihood that a mammal that will respond therapeutically to a method of treating cancer comprising administering an EGFR modulator, wherein the method comprises (a) measuring in the mammal the level of at least one biomarker selected from epiregulin and amphiregulin, (b) exposing a biological sample from the mammal to the EGFR modulator, and (c) following the exposing of step (b), measuring in the biological sample the level of the at least one biomarker, wherein an increase in the level of the at least one biomarker measured in step (c) compared to the level of the at least one biomarker measured in step (a) indicates an increased likelihood that the mammal will respond therapeutically to the method of treating cancer.
摘要翻译： EGFR生物标志物可用于预测将对治疗癌症治疗的治疗反应的哺乳动物的可能性的方法，其包括施用EGFR调节剂，其中所述方法包括（a）在哺乳动物中测量至少一种选自上皮蛋白的生物标志物 （b）将生物样品从哺乳动物暴露于EGFR调节剂，和（c）在暴露步骤（b）之后，在生物样品中测量至少一种生物标志物的水平，其中增加 与步骤（a）中测量的至少一种生物标志物的水平相比，在步骤（c）中测量的至少一种生物标志物的水平表明哺乳动物对治疗癌症的方法治疗反应的可能性增加。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.021 秒)
